People with early-stage Parkinson’s disease may be about 70% less likely to catch the common cold than those with other common brain diseases, a Japanese study suggests. The study, “Are patients with Parkinson’s disease at a lower risk of catching the common cold? Propensity score matching,” was published…
Krill oil, which comes from a shrimp-like animal, protected dopamine-producing neurons from age-related degeneration and boosted neurologic processes dependent on the brain chemical messenger in a worm model of Parkinson’s disease, a study showed. The production of dopamine is gradually impaired in people with Parkinson’s due to the progressive…
A gene therapy designed to track down and keep overactive brain cells in check was able to lower the number of seizures in a mouse study of epilepsy. This therapy is also notable in sparing healthy brain tissue by switching itself off after its work is done. Should early work…
Add-on treatment with a low dose of zonisamide, an anti-seizure medication, failed to significantly ease tremor in a pilot study of people with a tremor-dominant form of Parkinson’s disease. However, when researchers preformed their analysis and included all people — even those who dropped out of the study…
A request to launch a first Phase 1/2 clinical trial of a stem cell-based therapy in people with Parkinson’s disease has been approved by the Swedish Medical Products Agency. The therapy, called STEM-PD, consists of stem cell-derived dopamine-producing, or dopaminergic, neurons that are expected to replace the dopaminergic neurons that are…
Using simulated images, researchers have developed a method that may allow them to quantify how much dopamine transporter — a protein that pumps the chemical messenger dopamine into cells — there is in brain regions linked to Parkinson’s disease. The method can glean information from a single-photon emission…
People who go on to develop a neurodegenerative disease such as Parkinson’s may experience poorer overall health and show signs of disease many years before they get diagnosed, according to a study from the University of Cambridge in the U.K. For those with Parkinson’s, grip strength in both hands…
Two small molecules in the pipeline of Lucy Therapeutics helped nerve cells (neurons) keep their mitochondria healthier and reduced the levels of alpha-synuclein, a protein that builds as toxic clumps in the brain of people with Parkinson’s disease. These molecules, called LucyTx-1209 and LucyTx-1212, also were seen…
Gb Sciences has identified a handful of mixtures that contain just enough cannabinoids — the active compounds of the cannabis plant — to prevent death in lab-grown nerve cells and help lessen motor symptoms in a zebrafish model of Parkinson’s disease. Out of more than 60 mixtures…
Dosing has begun in LIGHTHOUSE, a Phase 3 clinical trial testing BIIB122 — an experimental inhibitor of LRRK2 being developed by Biogen and Denali Therapeutics — in patients with early-stage Parkinson’s disease. The study (NCT05418673), underway at two clinical sites in Colorado and Florida, is recruiting up…
Get regular updates to your inbox.
